What is Trasylol Patch?
Trasylol (Aprotinin) is a serine protease inhibitor obtained from bovine (cow) lung or pancreas and is used to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass (CPB) in the course of coronary artery bypass graft surgery (CABG).
Recently studies have linked Trasylol to an increased risk of kidney damage,
heart attacks, and strokes. If you or a loved one have experienced complications
after cardiopulmonary bypass (CPB) or coronary artery bypass graft surgery
(CABG) you should contact your medical providers to determine if Trasylol was
used during the procedure. If Trasylol was used and you or a loved experienced
complications you may be entitled to compensation. To learn more about your
legal rights or to inquire about an Trasylol class action lawsuit or individual
lawsuit contact the Trasylol lawyers of Ennis & Ennis today.
The United States Food and Drug Administration (FDA) issued a Trasylol public health advisory on February 8, 2006. The advisory states that the FDA is conducting a safety evaluation for Trasylol to assess the drug’s risks. Doctors are warned to carefully weigh the potential benefits and risks of Trasylol before administering the drug to patients. Patients who take Trasylol should be monitored for toxicity to the kidneys, heart, and central nervous system. Adverse events must be promptly reported to Bayer or the FDA Medwatch program.
